Key facts
- Notable investors include Jolmo Investment, Tsing Stone Asset Management, Chang Development, 3E Bioventures (China), Indaco Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Indetek
- ·The full record, as it builds
Funding rounds
No funding rounds for Indetek are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Indetek
Manufacturer of innovative dermatology pharmaceuticals intended to address unmet needs in skin disease treatment. The company offers proprietary ILDS® transdermal technology and a comprehensive drug development pipeline, enabling dermatology patients worldwide to experience improved efficacy, safety, and therapeutic compliance.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2020
- Website
- indetek-lab.com/
- Ownership
- Privately Held (backing)
Indetek doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Indetek shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Indetek in its N-PORT filings yet. We sweep new filings monthly.